GlassScriptPhysician profile
Todd L Maus
NPI 1437134038
$1,717.86
in general payments reported to CMS, 2019-2025
16 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $112 · 2021: $146 · 2022: $355 · 2023: $350 · 2024: $206 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $300.78 | 2022-2025 | Idose, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Alcon Vision LLC | $280.00 | 2019-2025 | Clareon, Lensx |
| Sight Sciences, INC. | $202.10 | 2019-2022 | |
| Carl Zeiss Meditec, INC. | $180.79 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $151.15 | 2021-2023 | Cirrus Hd-Oct |
| Allergan, INC. | $141.62 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $140.19 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $101.75 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $60.60 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $34.52 | 2019 | |
| Astellas Pharma US INC | $27.51 | 2024 | Izervay |
| Rxsight INC | $25.61 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| New World Medical,INC. | $20.66 | 2021 | |
| Biotissue Holdings INC. | $20.43 | 2022 | |
| Bausch & Lomb Americas INC. | $16.25 | 2023 | Vyzulta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $13.90 | 2025 | Omidria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Maus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.